Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference.
TEZSPIRE is a registered trademark of Amgen Inc. and AstraZeneca.
https://www.azpicentral.com/pi.html?product=tezspire
